A precise timing of existing treatments could significantly improve treatment outcomes for one of the most aggressive cancers, suggests new research from researchers at UC San Diego. Read more
Uc San Diego Today - Nov 26
Mayo Clinic researchers have identified a specific immune cell that can be targeted to give a boost to standard immunotherapies for cancer. Two Read more
Medical News - Oct 29
OS Therapies Inc. (NYSE:OSTX), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, released survival data on Friday from the Phase 2b trial of its off-the-shelf immunotherapy candidate, OST-HER2, for pulmonary metastatic osteosarcoma, an aggressive type of bon... Read more
Benzinga - Oct 10
Tumor electrophysiological abnormalities, characterized by membrane potential dysregulation, ion channel network remodeling, and microenvironmental signaling interactions, are critical drivers of malignancy. Read more
Medical News - Aug 18
